Skip to main content
TDOC
NYSE Life Sciences

Teladoc Health Q1 Revenue Drops 2% as BetterHelp Segment Shrinks 9%, Reaffirms Outlook

feedReported by Reuters
Sentiment info
Negative
Importance info
7
Price
$5.64
Mkt Cap
$1.074B
52W Low
$4.4
52W High
$9.77
Market data snapshot near publication time

summarizeSummary

Teladoc Health reported a 2% year-over-year decline in Q1 revenue, with its BetterHelp segment revenue falling 9% and paying users decreasing. This continues a trend of revenue decrease and user metric decline previously noted in the company's 10-K. While the company slightly beat analyst expectations for Q1 revenue and adjusted EBITDA, and reaffirmed its full-year financial outlook, the ongoing contraction in its key BetterHelp segment presents a material challenge to its growth trajectory. Traders will monitor future reports for signs of stabilization or reversal in these core segments.

At the time of this announcement, TDOC was trading at $5.64 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $4.40 to $9.77. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


show_chartPrice Chart

Share this article

Copied!

feed TDOC - Latest Insights

TDOC
Apr 29, 2026, 4:53 PM EDT
Source: Reuters
Importance Score:
7
TDOC
Apr 07, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
TDOC
Mar 31, 2026, 5:19 PM EDT
Source: Reuters
Importance Score:
9
TDOC
Mar 30, 2026, 5:32 PM EDT
Filing Type: 8-K
Importance Score:
8
TDOC
Feb 26, 2026, 11:07 AM EST
Filing Type: 10-K
Importance Score:
7
TDOC
Feb 25, 2026, 4:04 PM EST
Filing Type: 8-K
Importance Score:
7
TDOC
Feb 18, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7